Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for Grade II-IV Steroid-Refractory Acute Graft-Versus-Host Disease
NCT07885228Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in Acute graft-versus-host disease (aGVHD), sponsored by Nanfang Hospital, Southern Medical University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
Acute graft-versus-host disease (aGVHD)
Beyond the preview
Go deeper on NCT07885228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885228.